中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 1
Jan.  2011

The immunological evaluation of hepatitis C virus vaccine

Research funding:

 

  • Published Date: 2011-01-20
  • Hepatitis C virus (HCV) is an enveloped positive-strand RNA virus in the family Flaviviridae with high mutation rate in the genome. Chronic infection causes chronic hepatitis, necrosis and fi brosis, which can progress to cirrhosis and hepatocellular carcinoma which is one of the biggest public heath problem. However, there is no effective vaccine update. The development of HCV vaccine is based on the evaluation of the specifi c immune responses against HCV and protection after challenge.

     

  • [1]Lindenbach B, Rice C.Unraveling hepatitis C virus replication from genome to function[J].Nature, 2005, 436 (7053) :933-938.
    [2]Lavanchy D, Purcell R, Hollinger FB, et al.Global surveillance and control of hepatitis C[J].Viral Hepat, 1999, 6 (1) :35-47.
    [3]De Francesco R, Migliaccio G.Challenges and succ-esses in developing new therapies for hepatitis C[J].Nature, 2005, 436 (7053) :953-960.
    [4]Lauer GM, Walker BD.Hepatitis C Virus Infection[J].N Engl J Med, 2001, 345 (1) :41-52.
    [5]Thimme R, Oldach D, Chang KM, et al.Determinants of viral clearance and persistence during acute hepatitis C virus infection[J].Exp Med, 2001, 194 (10) :1395-1406.
    [6]Cooper S, Erickson AL, Adams EJ, et al.Analysis of a successful immune response against hepatitis C virus[J].Immunity, 1999, 10 (4) :439-449.
    [7]Lechner F, Wong D, Dunbar P, et al.Analysis of successful immune responses in persons infected with hepatitis C virus[J].J Exp Med, 2000, 191 (9) :1499-1512.
    [8]Cox A, Mosbruger T, Lauer G, et al.Comprehensive analyses of CD8+T cell responses during longitudinal study of acute human hepatitis C[J].Hepatology, 2005, 42 (1) :104-112.
    [9]Lechner, F.Gruener N, Urbani S, et al.CD8+T lymphocyte responses are included during acute hepatitis C rirus infection but are not sustained[J].Eur J Immunol, 2000, 30 (9) :2 479-2487.
    [10]Bassett S, Guerra B, Brasky K, et al.Protective im-mune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection[J].Hepatology, 2001, 33 (6) :1479-1487.
    [11]Lanford, R, Guerra B, Chavez D, et al.Cross-genotype immunity to hepatitis C virus[J].J Virol, 2004, 78 (3) :1575-1581.
    [12]Thimme R, Oldach D, Chang K, et al.Determinants of viral clearance and persistence during acute hepatitis C virus infection[J].J Exp Med, 2001, 194 (10) :1395-1406.
    [13]Shoukry N, Cawthon A, Walker C.Cell-mediated im-munity and the outcome of hepatitis C virus infection[J].Annu Rev Microbiol, 2004, 58:391-424
    [14]Ulsenheimer A, Gerlach J, Gruener N, et al.Detection of functionally altered hepatitis C virus-specific CD4+T cells in acute and chronic hepatitis C[J].Hepatology, 2003, 37 (5) :1189-1198
    [15]Wedemeyer H, He X, Nascimbeni M, et al.Impaired effector function of hepatitis C virus-speci-c CD8+T cells in chronic hepatitis C virus Infection[J].J Immunol, 2002, 169 (6) :3447-3458.
    [16]Appay V, Dunbar P, Callan M, et al.Memory CD8+T cells vary in differentiation phenotype in different persistent virus infections[J].Nat Med, 2002, 8 (4) :379-385.
    [17]Choo Q, Kuo G, Ralston R, et al.Vaccination of chi-mpanzees against infection by the hepatitis C virus[J].Proc Natl Acad Sci, 1994, 91 (4) :1294-1298.
    [18]Farci P, Shimoda A, Wong D, et al.Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein[J].Proc Natl Acad Sci, 1996, 93 (26) :15394-15399.
    [19]Grakoui A, Shoukry N, Woollard D, et al.HCV persistence and immune evasion in the absence of memory T cell help[J].Science, 2003, 302 (5645) :659-662.
    [20]Thimme R, Bukh J, Spangenberg H, et al.Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease[J].Proc Natl Acad Sci, 2002, 99 (24) :15661-15668.
    [21]Folgori A, Capone S, Ruggeri L, et al.A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees[J].Nat Med, 2006, 12 (2) :190-197.
    [22]Grakoui A, Shoukry NH, Woollard DJ, et al.HCV persistence and immune evasion in the absence of memory T cell help[J].Science, 2003, 302 (5645) :659-662.
    [23]Neumann C, Thimme R.Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection[J].Genes Immun, 2007, 8 (3) :181-192.
    [24]Houghton M, Abrignani S.Prospects for a vaccine against the hepatitis C virus[J].Nature, 2005, 436 (7053) :961-966.
    [25]Rosa D, Campagnoli S, Moretto C, et al.A quantitative test to estimate neutralizing antibodies to the hepatitis C virus:cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells[J].Proc Natl Acad Sci, 1996, 93 (5) :1759-1763.
    [26]Bartosch B, Dubuisson J, Cosset F.Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1-E2 Envelope Protein Complexes[J].J Exp Med, 2003, 197 (5) :633-642.
    [27]Wakita T, Pietschmann T, Kato T, et al.Production of临床肝胆病杂志2011年第27卷第1期infectious hepatitis C virus in tissue culture from a cloned viral genome[J].Nat Med, 2005, 11 (7) :791-796.
    [28]Lindenbach B, Evans M, Syder A, et al.Complete replication of hepatitis C virus in cell culture[J].Science, 2005, 309 (5734) :623-626.
    [29]Stamataki Z, Coates S, Evans M, et al.Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies[J].Vaccine, 2007, 25 (45) :7773-7784.
    [30]Kreher C, Dittrich M, Guerkov R, et al.CD4+and CD8+cells in cryopreserved human PBMC maintain full functionality in cytokine C virus in cell culture[J].Science, 2005, 309 (5734) :623-626.
    [31]Diepolder H, Zachoval R, Hoffmann R, et al.Possible mechanism involving T lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection[J].Lancet, 1995, 346 (8981) :1 006-1007.
    [32]Rigopoulou E, Suri D, Chokshi S, et al.Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B:antiviral and immunological activity[J].Hepatology, 2005, 42 (5) :1028-1036.
    [33]Elmowalid G, Qiao M, Jeong S, et al.Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees[J].Proc Natl Acad Sci, 2007, 104 (20) :8427-8432.
    [34]Murata K, Lechmann M, Ming Q, et al.Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection[J].Proc Natl Acad Sci, 2003, 100 (11) :6753-6758
    [35]Simon B, Cornell K, Clark T, et al.DNA Vaccination Protects Mice against Challenge with Listeria monocytogenes Expressing the Hepatitis C Virus NS3 Protein[J].Infect Immun, 2003, 71 (11) :6372-6380.
    [36]Encke J, Findeklee J, Geib J, et al.Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection[J].Clin Exp Immunol, 2005, 142 (2) :362-369.
  • Relative Articles

    [1]Li ShouJuan, Wang Li, Chen Zhu, Hu ChaoXia, Wang Lei, Wu Bei, Zhu Li, Duan Meng. Association of genotype with cellular immunity and coagulation function in chronic hepatitis B virus infection patients with different disease spectrums in Sichuan,China[J]. Journal of Clinical Hepatology, 2020, 36(5): 1014-1018. doi: 10.3969/j.issn.1001-5256.2020.05.013
    [2]Zhao ZhiBin, Lian ZheXiong. Immunological pathogenesis of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2017, 33(11): 2112-2116. doi: 10.3969/j.issn.1001-5256.2017.11.012
    [3]Jia ZhanSheng. Retrospect and reflection: the past 30 years of research on hepatitis C prophylaxis and treatment[J]. Journal of Clinical Hepatology, 2015, 31(11): 1803-1806. doi: 10.3969/j.issn.1001-5256.2015.11.009
    [4]Zhang YanFang, Zhao DongMei, Zhang YanMin, Wang Wei, Zhao HongRu. An analysis of related factors for hepatitis C genotyping and sustained virologic response in Xingtai, China[J]. Journal of Clinical Hepatology, 2015, 31(11): 1845-1848. doi: 10.3969/j.issn.1001-5256.2015.11.018
    [5]Cui LiNa, Han Ying. Immunoregulatory effect of multipotent stem cells in liver injury and repair[J]. Journal of Clinical Hepatology, 2014, 30(9): 855-859. doi: 10.3969/j.issn.1001-5256.2014.09.005
    [6]Chen HuiJuan, Zhao ShouSong. Recent insights into the roles of regulatory T cells in viral hepatitis[J]. Journal of Clinical Hepatology, 2012, 28(11): 868-871.
    [7]Yin LanNing, Zhang YouCheng, Zhou XiaoWei, Zhang YuHuai, Zhang Lin. Clinical study of the role of glutamine in immunological function during postoperative obstructive jaundice[J]. Journal of Clinical Hepatology, 2012, 28(7): 506-508.
    [8]Gao LuHua, Nie QingHe. The present research situation and significance of HCV ADE[J]. Journal of Clinical Hepatology, 2011, 27(8): 885-887.
    [9]Lan HaiYun, Wang AiQin, Yin Wen. Advance in the research of experimental mouse model for hepatitis C virus[J]. Journal of Clinical Hepatology, 2011, 27(1): 36-39.
    [10]Yin Xiao, Wen Bo, Tan WenJie. Progress in the development and immunogenicity improvement of DNA vaccine against chronic HCV infection[J]. Journal of Clinical Hepatology, 2011, 27(1): 32-35.
    [11]Shi XiaoDong, Jiang Jing, Niu JunQi. Association of interleukin 28B(IL28B) polymorphisms with the outcomes of HCV infection[J]. Journal of Clinical Hepatology, 2011, 27(1): 28-31.
    [12]Gao LuHua, Nie QingHe. Detection of hepatitis C virus in the supernatant of human placenta trophoblastic cells and cell lysates[J]. Journal of Clinical Hepatology, 2011, 27(12): 1296-1300.
    [13]Wei Feng, Li JunQing, Zhou JunYing. Dendritic cells and hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(5): 549-552.
    [14]Qi ZhongTian. Hepatitis C virus infection and its therapeutic drugs[J]. Journal of Clinical Hepatology, 2011, 27(1): 15-18+27.
    [15]Yang RuiFeng, Wei Lai. Detection of hepatitis C virus infection[J]. Journal of Clinical Hepatology, 2011, 27(1): 1-7.
    [16]Jia ZhanSheng, Ma Li, Wei SanHua, Yao ZhiQiang. New ideas, challenges and strategies about research on hepatitis C vaccine[J]. Journal of Clinical Hepatology, 2011, 27(1): 8-14.
    [17]Tian Di, Xu XiaoYuan. Treatment of hepatitis C virus infection in HIV/HCV co-infected patients[J]. Journal of Clinical Hepatology, 2011, 27(5): 540-544.
    [18]Yan Yan, Xiu BingShui, Yin JiMing, Zhang HeQiu, Li Zhuo. Evaluation of cross-reactive antibody response to hypervariable region 1 of hepatitis C virus[J]. Journal of Clinical Hepatology, 2011, 27(8): 818-820.
    [19]Zhou Yun, Li Duan, Chen Lin, Zhao FuTao, Ma Li, Wang Hong, Pan Lei, Jia ZhanSheng. The construction of HCV multi-CTL epitopes dendritic cell vaccine and its effect of stimulating T cell response in vitro[J]. Journal of Clinical Hepatology, 2011, 27(1): 40-44.
    [20]Xu JingSheng, Gao JiaHong. The progress of chronic hepatitis:from virus to host[J]. Journal of Clinical Hepatology, 2010, 26(4): 353-357+370.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (4558) PDF downloads(1066) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return